Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoE-deficient mice

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 9, Issue 3, 2006, Pages 388-397

  Pospisilova, Nada ^a   Semecky, Vladimir ^a   Jamborova, Gabriela ^a   Pospechova, Katerina ^a   Solichova, Dagmar ^b   Andrys, Ctirad ^b   Zdansky, Petr ^b   Nachtigal, Petr ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; ENDOGLIN; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BIOCHEMISTRY; CONTROLLED STUDY; ENDOTHELIUM; EUTHANASIA; FEEDING; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STEREOLOGY;

ANIMALS; APOLIPOPROTEINS E; DIET, ATHEROGENIC; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRROLES;

EID: 33947543546     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cybulsky MI, Won D, Haidari M, Leukocyte recruitment to atherosclerotic lesions. Can J Cardiol, 20 Suppl B: 24B-28B, 2004.
2. Blann AD, Nadar SK, Lip GY, The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J, 24: 2166-2179, 2003.
3. Mallat Z, Gojova A, Marchiol-Fournigault C et al., Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res, 89: 930-934, 2001.
4. Ryan ST, Koteliansky VE, Gotwals PJ, Lindner V, Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res, 40: 37-46, 2003.
5. Letamendia A, Lastres P, Botella LM et al., Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. J Biol Chem, 273: 33011-33019, 1998.
6. Zhang H, Shaw AR, Mak A, Letarte M, Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol, 156: 564-573, 1996.
7. Adam PJ, Clesham GJ, Weissberg PL, Expression of endoglin mRNA and protein in human vascular smooth muscle cells. Biochem Biophys Res Commun, 247: 33-37, 1998.
8. St-Jacques S, Cymerman U, Pece N, Letarte M, Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology, 134: 2645-2657, 1994.
9. Lastres P, Bellon T, Cabanas C et al., Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol, 22: 393-397, 1992.
10. Kay NE, Bone ND, Tschumper RC et al., BCLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia, 16: 911-919, 2002.
11. Buhring HJ, Muller CA, Letarte M et al., Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia, 5: 841-847, 1991.
12. Duff SE, Li C, Garland JM, Kumar S, CD105 is important for angiogenesis: evidence and potential applications. Faseb J, 17: 984-992, 2003.
13. Conley BA, Smith JD, Guerrero-Esteo M et al., Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis, 153: 323-335, 2000.
14. Arnaud C, Mach F, Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss, 98: 661-666, 2005.
15. Seljeflot I, Tonstad S, Hjermann I, Arnesen H, Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis, 162: 179-185, 2002.
16. Cybulsky MI, Iiyama K, Li H et al., A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest, 107: 1255-1262, 2001.
17. Sukhova GK, Williams JK, Libby P, Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol, 22: 1452-1458, 2002.
18. Mallat Z, Tedgui A, The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives. Curr Opin Lipidol, 13: 523-529, 2002.
19. Blanco FJ, Santibanez JF, Guerrero-Esteo M et al., Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol, 204: 574-584, 2005.
20. Ma X, Labinaz M, Goldstein J et al., Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol, 20: 2546-2552, 2000.
21. Laufs U, Gertz K, Huang P et al., Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke, 31: 2442-2449, 2000.
22. Sparrow CP, Burton CA, Hernandez M et al., Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol, 21: 115-121, 2001.
23. Nachtigal P, Semecky V, Kopecky M et al., Application of stereological methods for the quantification of VCAM-1 and ICAM-1 expression in early stages of rabbit atherogenesis. Pathol Res Pract, 200: 219-229, 2004.
24. Nachtigal P, Semecky V, Gojova A et al., The application of stereological methods for the quantitative analysis of the atherosclerotic lesions in rabbits. Image Anal Stereol, 21: 165-174, 2002.
25. Weibel E. Stereological methods, Vol 1. Practical methods for biology morphometry.: Academic Press, 1979.
26. Gundersen HJ, Bagger P, Bendtsen TF et al., The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Apmis, 96: 857-881, 1988.
27. Reddick RL, Zhang SH, Maeda N, Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Tromb, 14: 141-147, 1994.
28. Bellon T, Corbi A, Lastres P et al., Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol, 23: 2340-2345, 1993.
29. Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE, Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res, 18: 1485-1500, 1998.
30. Bea F, Blessing E, Bennett B et al., Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol, 22: 1832-1837, 2002.
31. Bea F, Blessing E, Shelley MI et al., Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis, 167: 187-194, 2003.
32. Ikeda U, Shimada K, Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets Cardiovasc Haematol Disord, 1: 51-58, 2001.
33. Cybulsky MI, Lichtman AH, Hajra L, Iiyama K, Leukocyte adhesion molecules in atherogenesis. Clin Chim Acta, 286: 207-218, 1999.
34. Choudhury RP, Carrelli AL, Stern JD et al., Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice. J Vasc Res, 41: 75-83, 2004.
35. Wang YX, Martin-McNulty B, Huw LY et al., Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis, 162: 23-31, 2002.
36. Fu T, Borensztajn J, Simvastatin causes the formation of cholesterol-rich remnants in mice lacking apoE. Biochem Biophys Res Commun, 341: 1172-1176, 2006.
37. Wierzbicki AS, Poston R, Ferro A, The lipid and non-lipid effects of statins. Pharmacol Ther, 99: 95-112, 2003.
38. Collins T, Cybulsky MI, NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest, 107: 255-264, 2001.
39. Rius C, Smith JD, Almendro N et al., Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood, 92: 4677-4690, 1998.
40. Nachtigal P, Pospisilova N, Pospechova K et al., MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/ - mouse model of atherosclerosis. Life Sci, 78: 1983-1989, 2006.
41. Lutgens E, Gijbels M, Smook M et al., Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol, 22: 975-982, 2002.
42. Heimark RL, Twardzik DR, Schwartz SM, Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science, 233: 1078-1080, 1986.
43. McCaffrey TA, Du B, Fu C et al., The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol, 31: 1627-1642, 1999.
44. Li C, Hampson IN, Hampson L et al., CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. Faseb J, 14: 55-64, 2000.
45. Gamble JR, Bradley S, Noack L, Vadas MA, TGF-beta and endothelial cells inhibit VCAM-1 expression on human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 15: 949-955, 1995.
46. Guerrero-Esteo M, Lastres P, Letamendia A et al., Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol, 78: 614-623, 1999.